Literature DB >> 19915386

Zoledronic acid decreases mRNA six-transmembrane epithelial antigen of prostate protein expression in prostate cancer cells.

M T Valenti1, S Giannini, L Donatelli, G Realdi, V Lo Cascio, L Dalle Carbonare.   

Abstract

BACKGROUND: Zoledronic acid (Zol) is used successfully to inhibit bone resorption in tumor bone disease of various human cancer. Zol inhibits the mevalonate pathway and other potential targets include the inhibition of tyrosine phosphatase activity, disruption of metalloproteinase, secretion and down-regulation of the catalytic subunit of telomerase (hTERT). The six-transmembrane epithelial antigen of prostate protein (STEAP) is a new marker highly expressed at all phases of prostate cancer. AIM: Here, we analyzed for the first time the effect of Zol on STEAP gene expression in prostate cancer cells.
MATERIAL AND METHODS: We evaluated the effects of Zol in STEAP gene expression by RT real time PCR in androgen-sensitive (LNCaP) and androgen-non-sensitive (PC3 and DU145) cell lines. To confirm the pro-apoptotic effect of Zol, we also analyzed the caspase-3 gene expression, that resulted up-regulated in cancer cell apoptosis.
RESULTS: Zol strongly decreased cell viability and lowered STEAP gene expression in a dose-dependent manner. In addition, this effect was accompanied by an increase of apoptotic index and an up-regulation of caspase-3 gene expression.
CONCLUSION: Zol may affect cancer cells also by targeting the gene expression of STEAP.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19915386     DOI: 10.1007/BF03345787

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  20 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Real time quantitative PCR.

Authors:  C A Heid; J Stevens; K J Livak; P M Williams
Journal:  Genome Res       Date:  1996-10       Impact factor: 9.043

3.  Alterations in mRNA expression of apoptosis-related genes BCL2, BAX, FAS, caspase-3, and the novel member BCL2L12 after treatment of human leukemic cell line HL60 with the antineoplastic agent etoposide.

Authors:  Kostas V Floros; Hellinida Thomadaki; Dimitra Florou; Maroulio Talieri; Andreas Scorilas
Journal:  Ann N Y Acad Sci       Date:  2006-12       Impact factor: 5.691

4.  Expression and functional analysis of voltage-activated Na+ channels in human prostate cancer cell lines and their contribution to invasion in vitro.

Authors:  M E Laniado; E N Lalani; S P Fraser; J A Grimes; G Bhangal; M B Djamgoz; P D Abel
Journal:  Am J Pathol       Date:  1997-04       Impact factor: 4.307

Review 5.  Ion channels in death and differentiation of prostate cancer cells.

Authors:  N Prevarskaya; R Skryma; G Bidaux; M Flourakis; Y Shuba
Journal:  Cell Death Differ       Date:  2007-05-04       Impact factor: 15.828

6.  The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation.

Authors:  Andreas Guenther; Sharon Gordon; Markus Tiemann; Renate Burger; Frank Bakker; Jonathan R Green; Wolfgang Baum; Anke J Roelofs; Michael J Rogers; Martin Gramatzki
Journal:  Int J Cancer       Date:  2010-01-01       Impact factor: 7.396

7.  The effects on hTERT gene expression is an additional mechanism of amino-bisphosphonates in prostatic cancer cells.

Authors:  Maria Teresa Valenti; Luca Dalle Carbonare; Francesco Bertoldo; Luca Donatelli; Vincenzo Lo Cascio
Journal:  Eur J Pharmacol       Date:  2007-11-01       Impact factor: 4.432

8.  STEAP mRNA detection in serum of patients with solid tumours.

Authors:  M T Valenti; L Dalle Carbonare; L Donatelli; F Bertoldo; B Giovanazzi; F Caliari; V Lo Cascio
Journal:  Cancer Lett       Date:  2008-09-14       Impact factor: 8.679

9.  ACRATA: a novel electron transfer domain associated to apoptosis and cancer.

Authors:  Luis Sanchez-Pulido; Ana M Rojas; Alfonso Valencia; Carlos Martinez-A; Miguel A Andrade
Journal:  BMC Cancer       Date:  2004-12-29       Impact factor: 4.430

10.  Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostatic cells.

Authors:  M Goffinet; M Thoulouzan; A Pradines; I Lajoie-Mazenc; Carolyn Weinbaum; J C Faye; S Séronie-Vivien
Journal:  BMC Cancer       Date:  2006-03-15       Impact factor: 4.430

View more
  1 in total

1.  Knockdown of STEAP1 inhibits cell growth and induces apoptosis in LNCaP prostate cancer cells counteracting the effect of androgens.

Authors:  Inês Margarida Gomes; Sandra Moreira Rocha; Carlos Gaspar; Maria Inês Alvelos; Cecília Reis Santos; Sílvia Socorro; Cláudio Jorge Maia
Journal:  Med Oncol       Date:  2018-02-20       Impact factor: 3.064

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.